Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial-Reference-Cited by-同舟云学术

Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial

Published:2018-07-19 Issue:5 Volume:108 Page:499-509
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Ohmachi Ken,Tobinai Kensei,Kinoshita Tomohiro,Ishikawa Takayuki,Hatake Kiyohiko,Ichikawa Satoshi,Ohmine Ken,Kamitsuji Yuri,Choi Ilseung,Chou Takaaki,Tsukasaki Kunihiro,Kumagai Kyoya,Taniwaki Masafumi,Uchida Toshiki,Kikukawa Yoshitaka,Kubo Kohmei,Mihara Keichiro,Tsukamoto Norifumi,Izutsu Koji,Yoshida Isao,Ishida Fumihiro,Usui Noriko,Iida Shinsuke,Murayama Tohru,Ueda Eisuke,Kuriki Hiroshi,Ando Kiyoshi

Funder

Chugai Pharmaceutical Co Ltd.

F. Hoffmann-La Roche Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-018-2497-0/fulltext.html

Reference30 articles.

1. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.

2. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23.